Perrigo Company plc (NYSE:PRGO) Given Average Recommendation of “Hold” by Analysts

by · The Markets Daily

Shares of Perrigo Company plc (NYSE:PRGO – Get Free Report) have been given an average rating of “Hold” by the six ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $19.3333.

PRGO has been the topic of several recent analyst reports. Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings raised Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th.

Check Out Our Latest Stock Report on Perrigo

Perrigo Stock Down 1.5%

Shares of Perrigo stock traded down $0.20 during trading hours on Friday, reaching $13.28. 172,532 shares of the company’s stock were exchanged, compared to its average volume of 3,072,589. The company has a 50 day moving average of $12.55 and a two-hundred day moving average of $11.39. Perrigo has a fifty-two week low of $9.23 and a fifty-two week high of $22.65. The company has a current ratio of 2.32, a quick ratio of 1.32 and a debt-to-equity ratio of 1.31. The stock has a market cap of $1.84 billion, a P/E ratio of -1.06, a P/E/G ratio of 1.55 and a beta of 0.59.

Perrigo (NYSE:PRGO – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.11. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the business earned ($0.06) earnings per share. Perrigo’s quarterly revenue was down 3.1% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, sell-side analysts forecast that Perrigo will post 2.18 EPS for the current fiscal year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th were paid a dividend of $0.29 per share. The ex-dividend date was Friday, August 28th. This represents a $1.16 annualized dividend and a dividend yield of 8.7%. Perrigo’s payout ratio is currently -9.27%.

Institutional Investors Weigh In On Perrigo

Several hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares in the last quarter. Covestor Ltd increased its position in shares of Perrigo by 14.4% during the fourth quarter. Covestor Ltd now owns 8,991 shares of the company’s stock valued at $125,000 after acquiring an additional 1,129 shares in the last quarter. Parrish Capital LLC increased its position in shares of Perrigo by 4.3% during the second quarter. Parrish Capital LLC now owns 33,896 shares of the company’s stock valued at $352,000 after acquiring an additional 1,384 shares in the last quarter. Huntington National Bank raised its holdings in Perrigo by 99.9% in the 4th quarter. Huntington National Bank now owns 4,741 shares of the company’s stock worth $66,000 after acquiring an additional 2,369 shares during the last quarter. Finally, KBC Group NV lifted its position in Perrigo by 61.3% in the 1st quarter. KBC Group NV now owns 6,283 shares of the company’s stock valued at $67,000 after acquiring an additional 2,388 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

About Perrigo

(Get Free Report)

Perrigo Company plc is a global consumer self-care company that develops, manufactures and markets over-the-counter (OTC) products and other nonprescription health and wellness products. Its portfolio spans consumer health categories including pain relief, allergy and cold remedies, digestive health, skin care, oral care, vitamins and supplements, and women’s health.

The company sells products under both its own brands and retailer-owned store brands through pharmacies, supermarkets, mass merchants, e-commerce channels and other outlets.

Read More